Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- Check3 days agoChange DetectedRecruitment status updated and new study sections added, with a revised Intervention/Treatment area and a version note (v3.6.0).SummaryDifference0.4%

- Check11 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the page's documentation/versioning. No substantive changes to study information or layout are implied.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now displays a newer revision tag: Revision: v3.5.4, replacing the prior v3.5.3.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page's revision changed from v3.5.2 to v3.5.3, indicating a small backend update. It reflects an internal version bump rather than a change to the displayed study information.SummaryDifference0.0%

- Check61 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check89 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.